Put companies on watchlist
Formycon AG
ISIN: DE000A1EWVY8
WKN: A1EWVY
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Formycon AG · ISIN: DE000A1EWVY8 · EQS - adhoc news (165 News)
Country: Germany · Primary market: Germany · EQS NID: 1879795
12 April 2024 07:27PM

Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year


EQS-Ad-hoc: Formycon AG / Key word(s): Preliminary Results/Forecast
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year

12-Apr-2024 / 19:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014

Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year

Planegg-Martinsried, Germany, 12. April 2024 – Based on preliminary and unaudited figures for the 2023 financial year, Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Company") expects EBITDA to be around EUR 1.5 million (guidance: EUR -5 million to EUR -15 million) due to increased revenues and lower investments in the COVID-19 project FYB207 than originally anticipated. The Company further expects a consolidated net result of around EUR 75.8 million (guidance: EUR 50 million to EUR 60 million) due to an one-off, non-cash adjustment in the context of financial income.  The working capital is expected to amount to around EUR 38.9 million (guidance: EUR 15 million to EUR 25 million). At around EUR 77.7 million, the revenue for 2023 is expected to be within the forecasted range of EUR 75 million and EUR 85 million.

For the 2024 financial year, the Company expects revenues of between EUR 55 million and EUR 65 million and EBITDA of between EUR -15 million and EUR -25 million. Adjusted EBITDA, which the Company will use as a new key performance indicator in future financial reporting instead of the net result, is expected to be between EUR -5 million and EUR -15 million in the 2024 financial year. The Company expects working capital for 2024 to be between EUR 10 million and EUR 20 million.

With respect to the definition of the alternative performance measures EBITDA and working capital, please refer to the corresponding definition in the Company's 2022 annual report (page 73 of the combined management report), which is published on the Company's website in the "Investors" section. Adjusted EBITDA is defined as EBITDA including the at-equity result from Bioeq AG, which is under joint management.

The Company will publish the final figures and the annual report for the 2023 financial year on 25 April 2024.

Contact:
Sabrina Müller
Director Investor Relations and Corporate Communications
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

phone +49 (0) 89 – 86 46 67 149 | fax + 49 (0) 89 – 86 46 67 110
Sabrina.Mueller@formycon.com // www.formycon.com

 

Disclaimer
Certain statements contained in this release may constitute "forward-looking statements" that involve a number of risks and uncertainties. Forward-looking statements can generally be identified by the use of the words "may," "will," "should," "plan," "expect," "anticipate," "estimate," "believe," "intend," "project," or "aim," or the negative of these words or other variations of these words or comparable terminology. Forward-looking statements are based on assumptions, forecasts, estimates, projections, opinions or plans that, by their nature, are subject to significant risks and uncertainties and contingencies that are subject to change. The Company does not and will not give any assurance that any forward-looking statement will be achieved or prove to be accurate. Actual future business, financial condition, results of operations and prospects may differ materially from those projected or anticipated in the forward-looking statements. Subject to applicable legal requirements, neither the Company nor any other person intends to update, review, revise or revise any forward-looking statements in this release to reflect actual events or developments, whether as a result of new information becoming available, new developments occurring in the future or otherwise, nor does it undertake any such obligation.



End of Inside Information

12-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1879795

 
End of Announcement EQS News Service

1879795  12-Apr-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1879795&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Formycon AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.